By Paul Tullis — 2021
Regulators will soon grapple with how to safely administer powerful psychedelics for treating depression and post-traumatic stress disorder.
Read on www.nature.com
CLEAR ALL
In a recent UK trial, 12 patients with major depression took a pill quite different to commonly prescribed antidepressants: 25mg of psilocybin, the psychedelic compound found in magic mushrooms.
1
At Imperial College we’ve been comparing psilocybin to conventional antidepressants—and the results are likely to be game-changing.
A new brain-scan study helps explain how psilocybin works—and why it holds promise as a treatment for depression, addiction and post-traumatic stress.
How magic mushrooms expand consciousness.
2
These results support a recent model proposing that psychedelics reduce the ‘precision-weighting of priors’, thus altering the balance of top-down versus bottom-up information passing.
Research into psychedelics, shut down for decades, is now yielding exciting results.
Near-death experiences (NDEs) are complex subjective experiences, which have been previously associated with the psychedelic experience and more specifically with the experience induced by the potent serotonergic, N,N-Dimethyltryptamine (DMT).
The scientists hope their long-awaited study on LSD in humans will open the floodgates to further research into psychedelics.